CN112888706A - 包含基于tim-3的嵌合蛋白的组合疗法 - Google Patents

包含基于tim-3的嵌合蛋白的组合疗法 Download PDF

Info

Publication number
CN112888706A
CN112888706A CN201980070366.7A CN201980070366A CN112888706A CN 112888706 A CN112888706 A CN 112888706A CN 201980070366 A CN201980070366 A CN 201980070366A CN 112888706 A CN112888706 A CN 112888706A
Authority
CN
China
Prior art keywords
cancer
domain
binding
chimeric protein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980070366.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·施赖伯
G·弗罗姆
S·达西瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of CN112888706A publication Critical patent/CN112888706A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980070366.7A 2018-08-29 2019-08-29 包含基于tim-3的嵌合蛋白的组合疗法 Pending CN112888706A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862724597P 2018-08-29 2018-08-29
US201862724600P 2018-08-29 2018-08-29
US62/724,597 2018-08-29
US62/724,600 2018-08-29
US201862734951P 2018-09-21 2018-09-21
US201862734950P 2018-09-21 2018-09-21
US62/734,950 2018-09-21
US62/734,951 2018-09-21
US201962793235P 2019-01-16 2019-01-16
US62/793,235 2019-01-16
US201962832830P 2019-04-11 2019-04-11
US62/832,830 2019-04-11
US201962890217P 2019-08-22 2019-08-22
US62/890,217 2019-08-22
PCT/US2019/048916 WO2020047322A1 (en) 2018-08-29 2019-08-29 Combination therapies comprising tim-3-based chimeric proteins

Publications (1)

Publication Number Publication Date
CN112888706A true CN112888706A (zh) 2021-06-01

Family

ID=69643783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980070366.7A Pending CN112888706A (zh) 2018-08-29 2019-08-29 包含基于tim-3的嵌合蛋白的组合疗法

Country Status (9)

Country Link
US (1) US20210179689A1 (https=)
EP (1) EP3844185A4 (https=)
JP (1) JP2022503621A (https=)
CN (1) CN112888706A (https=)
AU (1) AU2019328305A1 (https=)
CA (1) CA3109349A1 (https=)
IL (1) IL281123A (https=)
MX (1) MX2021002291A (https=)
WO (1) WO2020047322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160166685A1 (en) * 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107208099A (zh) * 2015-02-06 2017-09-26 热生物制品有限公司 共表达疫苗和共刺激分子的载体
CN108350055A (zh) * 2015-10-01 2018-07-31 热生物制品有限公司 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
CN108368174A (zh) * 2015-11-23 2018-08-03 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009812A (es) * 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160166685A1 (en) * 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107208099A (zh) * 2015-02-06 2017-09-26 热生物制品有限公司 共表达疫苗和共刺激分子的载体
CN108350055A (zh) * 2015-10-01 2018-07-31 热生物制品有限公司 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
CN108368174A (zh) * 2015-11-23 2018-08-03 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JULIAN A MARIN-ACEVEDO等: "Next generation of immune checkpoint therapy in cancer: new developments and challenges", J HEMATOL ONCOL, vol. 11, no. 1, pages 1 - 20, XP055642850, DOI: 10.1186/s13045-018-0582-8 *
郭振红;曹雪涛;: "肿瘤免疫细胞治疗的现状及展望", 中国肿瘤生物治疗杂志, vol. 23, no. 02, pages 6 - 17 *

Also Published As

Publication number Publication date
EP3844185A1 (en) 2021-07-07
JP2022503621A (ja) 2022-01-12
MX2021002291A (es) 2021-05-27
EP3844185A4 (en) 2022-10-19
AU2019328305A1 (en) 2021-03-04
US20210179689A1 (en) 2021-06-17
IL281123A (en) 2021-04-29
CA3109349A1 (en) 2020-03-05
WO2020047322A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
CN110381983B (zh) 基于tigit和light的嵌合蛋白
CN112839952A (zh) 包含基于pd-1的嵌合蛋白的组合疗法
CN108350055A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
CN113747947A (zh) 组合疗法
US20200071380A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
US20240122983A1 (en) Flt3l-based chimeric proteins
CN114126663A (zh) Nk细胞定向的嵌合蛋白
CN112912384A (zh) 组合疗法
CN110290798A (zh) 基于vsig8的嵌合蛋白
US20240299492A1 (en) Combination therapies with sirp alpha-based chimeric proteins
US20200069733A1 (en) Flt3l-based chimeric proteins
CN112888706A (zh) 包含基于tim-3的嵌合蛋白的组合疗法
CN117355336A (zh) 基于SIRP α的嵌合蛋白的联合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210601

WD01 Invention patent application deemed withdrawn after publication